RC
ALXN

RegentAtlantic Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

RegentAtlantic Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-289
Closed -$53.5K – 1045
2014
Q4 		$53.5K Buy
+289
New +$53.6K ﹤0.01% 570

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

RegentAtlantic Capital's ALXN Position: Q1 2015 in Review

RegentAtlantic Capital sold out of Alexion Pharmaceuticals (ALXN) in Q1 2015, closing a stake of 289 shares — an estimated $53.5K sold.

RegentAtlantic Capital first reported a position in ALXN in Q4 2014 and held it in 1 quarter. The position peaked at $53.5K in Q4 2014. 565 funds tracked by Wall St. Rank hold ALXN as of Q1 2015.

  • RegentAtlantic Capital reported no remaining Alexion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • RegentAtlantic Capital sold 289 Alexion Pharmaceuticals shares in Q1 2015, an estimated $53.5K.
  • RegentAtlantic Capital first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • RegentAtlantic Capital's Alexion Pharmaceuticals position peaked at $53.5K in Q4 2014.
  • 565 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2015.

Based on RegentAtlantic Capital's 13F filing for Q1 2015, filed 27 Apr 2015.